Prior immunity wasn't enough. The new vaccines added a meaningful layer.
Even in a nation where most adults carry some memory of COVID-19 through prior infection or earlier vaccination, the newest shots still found room to protect. A study spanning seven states and more than 111,000 medical encounters found that the 2025-2026 COVID vaccines reduced hospitalization risk by 55 percent and emergency care visits by 50 percent among immunocompetent adults — a reminder that accumulated immunity and updated vaccination are not the same thing. The virus continues to evolve, and so does the human effort to meet it.
- Between 390,000 and 550,000 Americans were hospitalized for COVID in a single year, even as widespread prior immunity was assumed to be blunting the disease's worst edges.
- Adults 65 and older bore the heaviest weight, accounting for two-thirds of all hospitalizations in the study — a population for whom the margin between sick and critically ill remains dangerously thin.
- Researchers compared vaccination rates among 111,000 patients who tested positive versus negative for COVID, and the gap was stark: vaccinated people were far more likely to be in the negative column.
- The updated vaccines delivered roughly 50-55 percent protection against severe outcomes, holding steady across age groups and arriving at a median of just six and a half weeks post-vaccination.
- Scientists caution this is an interim snapshot — a season's early data — and call for longer observation across larger populations as new variants continue to reshape the threat.
Between September and December 2025, researchers monitoring COVID-19 across seven states found that the newest vaccines were earning their place. Drawing on more than 111,000 emergency, urgent care, and hospital encounters, the study showed the 2025-2026 shots reduced hospitalization risk by 55 percent and cut emergency care visits by half among immunocompetent adults. What made the finding notable was the backdrop: most Americans already carried some protection from prior infections or earlier rounds of vaccination. The updated vaccines still added meaningful defense on top of that.
The data came from a network of 253 emergency and urgent care sites and 179 hospitals, all linked through a shared electronic health record system. Researchers identified patients with COVID-like symptoms, tested them, and compared vaccination rates between those who tested positive and those who didn't. Only 5 percent of positive cases had received the new vaccine, compared to 12 percent of negative cases — a 2.4-fold difference that translated directly into the protection estimates.
Older adults remained the most vulnerable. Among those 65 and older, the vaccine showed 48 percent effectiveness against emergency visits and 53 percent against hospitalization. This group made up two-thirds of all hospitalizations in the study window, with December 2025 marking the peak of both emergency visits and admissions.
The numbers sit against a sobering backdrop: from October 2024 through September 2025, COVID sent between 390,000 and 550,000 Americans to the hospital — a burden that persisted despite substantial existing immunity across the population. Researchers applied careful statistical controls and excluded immunocompromised patients to isolate the vaccine's effect. Published in JAMA Network Open as an interim analysis, the study offers an early-season signal rather than a final verdict. The researchers themselves call for longer observation across larger groups. But the direction of the data is clear: updated vaccination continues to matter, even when prior immunity is already in place.
Between early September and the end of December 2025, researchers tracking COVID-19 across seven states found something worth noting: the newest vaccines were working. In a study of more than 111,000 medical encounters—emergency room visits, urgent care appointments, and hospital admissions—the 2025-2026 COVID vaccines reduced the risk of hospitalization by 55 percent among immunocompetent adults. They also cut the odds of needing emergency or urgent care by half. These numbers matter because they arrived in a landscape where most Americans already carried some protection from prior infections or earlier vaccinations. The new shots still added meaningful defense.
The research drew from a network of 253 emergency and urgent care facilities and 179 hospitals spread across seven states, all feeding data into an electronic health record system. Researchers identified adults who came in with COVID-like symptoms, tested them for the virus, and then compared vaccination rates between those who tested positive and those who didn't. The pattern was clear: only 5 percent of people who tested positive for COVID had received the 2025-2026 vaccine beforehand, while 12 percent of those who tested negative had been vaccinated. That gap—a 2.4-fold difference—is what the math translates into: 50 percent protection against emergency care encounters, 55 percent against hospitalization.
The protection held across age groups. Among adults 65 and older, who face the steepest risk of severe disease, the vaccine delivered 48 percent effectiveness against emergency department and urgent care visits, and 53 percent against hospitalization. The median time since vaccination was roughly six and a half weeks. These older adults accounted for two-thirds of all hospitalizations in the study period, and women made up 54 percent of those cases. The highest volume of both emergency visits and hospital admissions occurred in December 2025, the final month of the observation window.
Context matters here. From October 2024 through September 2025—the year before this study began—COVID sent between 390,000 and 550,000 Americans to the hospital. That's a staggering ongoing burden, even in a population with substantial existing immunity. The virus keeps changing. New variants emerge regularly, which is why public health officials update the vaccines each year to match circulating strains. The question researchers needed to answer was whether those updates actually worked in the real world, not just in laboratory conditions. This study provided that answer.
The research team applied statistical controls for age, sex, race and ethnicity, calendar time, and geographic region to isolate the vaccine's effect. They excluded immunocompromised patients, people who'd received multiple doses of the new vaccine, and those vaccinated less than a week before their encounter. The study was published in JAMA Network Open and represents what researchers call an interim analysis—a snapshot from early in the vaccination season. The findings suggest the updated vaccines are doing their job, but the researchers themselves note that longer-term observation of larger populations would strengthen confidence in these estimates. For now, the data point in one direction: vaccination continues to matter, even when prior immunity is already in place.
Notable Quotes
The 2025-2026 COVID-19 vaccines provided meaningful additional protection against medically attended COVID-19 among immunocompetent adults in the United States, even in a population with prior immunity from previous infections or vaccinations.— Study researchers, JAMA Network Open
The Hearth Conversation Another angle on the story
Why does this study matter if most people already had some immunity from past infections or vaccines?
Because 390,000 to 550,000 people still ended up hospitalized in the year before this study. Prior immunity wasn't enough. The new vaccines added a meaningful layer on top of what people already had.
What does 55 percent effectiveness actually mean in practical terms?
It means if you're vaccinated, your odds of ending up in the hospital with COVID are about half what they'd be unvaccinated. It's not perfect protection, but it's substantial.
The study only ran through December. Why release findings so early?
Because vaccination season happens in fall and winter. Public health officials need to know if the updated vaccines are working while people are still deciding whether to get them. Waiting for a full year of data would mean missing the window when people actually need the information.
Why did only 5 percent of people who tested positive have the new vaccine, while 12 percent of negatives did?
That's the whole point. The vaccinated group had lower infection rates. The 2.4-fold difference between those groups is what translates into the 50 to 55 percent protection numbers.
Does this mean older people should prioritize getting vaccinated?
The data shows older adults face the greatest risk of severe disease and hospitalization. The vaccine worked for them too—53 percent protection against hospitalization. So yes, the case is particularly strong for that group.
What's the catch? Why isn't everyone getting vaccinated if it works?
The study doesn't address that. It just measures whether the vaccine works. Why people choose not to get it is a separate question entirely.